| CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer JS Nielsen, RA Sahota, K Milne, SE Kost, NJ Nesslinger, PH Watson, ... Clinical Cancer Research 18 (12), 3281-3292, 2012 | 550 | 2012 |
| Novel functions of the CD34 family JS Nielsen, KM McNagny Journal of Cell Science 121 (22), 3683-3692, 2008 | 534 | 2008 |
| The role of podocalyxin in health and disease JS Nielsen, KM McNagny Journal of the American Society of Nephrology 20 (8), 1669-1676, 2009 | 271 | 2009 |
| Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression A Somasiri, JS Nielsen, N Makretsov, ML McCoy, L Prentice, CB Gilks, ... Cancer research 64 (15), 5068-5073, 2004 | 184 | 2004 |
| Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer DA Wick, JR Webb, JS Nielsen, SD Martin, DR Kroeger, K Milne, ... Clinical Cancer Research 20 (5), 1125-1134, 2014 | 174 | 2014 |
| Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells R Doyonnas, JS Nielsen, S Chelliah, E Drew, T Hara, A Miyajima, ... Blood 105 (11), 4170-4178, 2005 | 151 | 2005 |
| Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines SD Martin, SD Brown, DA Wick, JS Nielsen, DR Kroeger, ... PloS one 11 (5), e0155189, 2016 | 143 | 2016 |
| CD34 is a key regulator of hematopoietic stem cell trafficking to bone marrow and mast cell progenitor trafficking in the periphery JS Nielsen, KM McNagny Microcirculation 16 (6), 487-496, 2009 | 142 | 2009 |
| The CD34-related molecule podocalyxin is a potent inducer of microvillus formation JS Nielsen, ML Graves, S Chelliah, AW Vogl, CD Roskelley, KM McNagny PLoS One 2 (2), e237, 2007 | 116 | 2007 |
| Tumor-infiltrating B cells and T cells: working together to promote patient survival JS Nielsen, BH Nelson Oncoimmunology 1 (9), 1623-1625, 2012 | 87 | 2012 |
| Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy KA Snyder, MR Hughes, B Hedberg, J Brandon, DC Hernaez, P Bergqvist, ... Breast Cancer Res 17 (1), 46, 2015 | 77 | 2015 |
| Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (α E/β 7 Integrin) in high-grade serous ovarian cancer JR Webb, DA Wick, JS Nielsen, E Tran, K Milne, E McMurtrie, BH Nelson Gynecologic oncology 118 (3), 228-236, 2010 | 75 | 2010 |
| ESRRA-C11orf20 Is a Recurrent Gene Fusion in Serous Ovarian Carcinoma J Salzman, RJ Marinelli, PL Wang, AE Green, JS Nielsen, BH Nelson, ... PLoS Biol 9 (9), e1001156, 2011 | 64 | 2011 |
| Multiplex droplet digital PCR quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma M Alcaide, S Yu, K Bushell, D Fornika, JS Nielsen, BH Nelson, KK Mann, ... Clinical Chemistry 62 (9), 1238-1247, 2016 | 54 | 2016 |
| Microfluidic devices and methods for use thereof in multicellular assays of secretion M Ricicova, KA Heyries, H Zahn, O Petriv, V Lecault, A Singhal, ... US Patent 10,725,024, 2020 | 53 | 2020 |
| Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer K Milne, RO Barnes, A Girardin, MA Mawer, NJ Nesslinger, A Ng, ... PloS one 3 (10), e3409, 2008 | 50 | 2008 |
| A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer SD Martin, DA Wick, JS Nielsen, N Little, RA Holt, BH Nelson Oncoimmunology 7 (1), e1371895, 2018 | 44 | 2018 |
| Polyfunctional T-Cell Responses Are Disrupted by the Ovarian Cancer Ascites Environment and Only Partially Restored by Clinically Relevant Cytokines E Tran, JS Nielsen, DA Wick, AV Ng, LDS Johnson, NJ Nesslinger, ... PloS one 5 (12), e15625, 2010 | 37 | 2010 |
| The cell surface mucin podocalyxin regulates collective breast tumor budding ML Graves, JA Cipollone, P Austin, EM Bell, JS Nielsen, CB Gilks, ... Breast Cancer Research 18 (1), 1-17, 2016 | 35 | 2016 |
| Toward personalized lymphoma immunotherapy: identification of common driver mutations recognized by patient CD8+ T cells JS Nielsen, CG Sedgwick, A Shahid, Z Zong, ZL Brumme, S Yu, L Liu, ... Clinical Cancer Research 22 (9), 2226-2236, 2016 | 35 | 2016 |
Brad H NelsonDirector, Deeley Research Centre, BC Cancer Agency在 bccancer.bc.ca 的电子邮件经过验证
